Lexeo Therapeutics
Clinical trials sponsored by Lexeo Therapeutics, explained in plain language.
-
Gene therapy targets heart damage in rare neurological disease
Disease control OngoingThis early-stage study tests a gene therapy called LX2006 in 8 people with Friedreich's ataxia who also have heart muscle disease. The treatment delivers a working copy of the frataxin gene to heart cells through a single IV infusion. Researchers will monitor safety and heart fun…
Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated May 17, 2026 06:46 UTC
-
Gene therapy trial hopes to fix heart muscle in rare genetic disease
Disease control OngoingThis early-stage trial tests a gene therapy called LX2020 in 10 adults with a rare, inherited heart condition (PKP2-ACM) that can cause dangerous heart rhythms and heart failure. The therapy is given once through a vein and aims to deliver a working copy of the PKP2 gene to heart…
Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated May 12, 2026 13:44 UTC
-
Gene therapy for rare heart disease: Long-Term safety check begins
Disease control ENROLLING_BY_INVITATIONThis study follows 10 people who already received the experimental gene therapy LX2020 for a genetic heart condition called arrhythmogenic cardiomyopathy. Researchers will monitor them for years to see if the treatment remains safe and continues to work. The goal is to understand…
Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated May 12, 2026 13:43 UTC